1. Drotrecogin Alfa (Activated) for the Treatment of Severe Sepsis and Septic Shock 
Todd W. Rice, MD, Gordon R. Bernard, MD 
The American Journal of the Medical Sciences 
Volume 328, Issue 4, Pages (October 2004)
DOI: /
Copyright © 2004 Southern Society for Clinical Investigation Terms and Conditions

2. Figure 1
Comparison of characteristics of PROWESS subjects enrolled prior to (n=720) and after (n=970) inception of the protocol amendment.43 Patients enrolled after the amendment were very similar to those enrolled before, with the exception of a smaller percentage having significant underlying disease, defined as disease likely to contribute to mortality as determined by an independent review committee.
The American Journal of the Medical Sciences  , DOI: ( / )
Copyright © 2004 Southern Society for Clinical Investigation Terms and Conditions

3. Figure 2
Mortality is compared according to time to initiation of drotrecogin alfa (activated) for the PROWESS trial,30 the retrospective MERCURY trial,57,58 and the prospective ENHANCE trial.59 Early administration is associated with decreased mortality in all three trials. * 24–48hours for the MERCURY group only.
The American Journal of the Medical Sciences  , DOI: ( / )
Copyright © 2004 Southern Society for Clinical Investigation Terms and Conditions